Wacker Bradley K, Dronadula Nagadhara, Zhang Jingwan, Dichek David A
From the Department of Medicine, University of Washington School of Medicine, Seattle.
Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):316-327. doi: 10.1161/ATVBAHA.116.308258. Epub 2016 Dec 8.
Gene therapy, delivered directly to the blood vessel wall, could potentially prevent atherosclerotic lesion growth and promote atherosclerosis regression. Previously, we reported that a helper-dependent adenoviral (HDAd) vector expressing apolipoprotein A-I (apoA-I) in carotid endothelium of fat-fed rabbits reduced early (4 weeks) atherosclerotic lesion growth. Here, we tested whether the same HDAd-delivered to the existing carotid atherosclerotic lesions-could promote regression.
Rabbits (n=26) were fed a high-fat diet for 7 months, then treated with bilateral carotid gene transfer. One carotid was infused with an HDAd expressing apoA-I (HDAdApoAI) and the other with a control nonexpressing HDAd (HDAdNull). The side with HDAdApoAI was randomized. Rabbits were then switched to regular chow, lowering their plasma cholesterols by over 70%. ApoA-I mRNA and protein were detected in HDAdApoAI-transduced arteries. After 7 weeks of gene therapy, compared with HDAdNull-treated arteries in the same rabbits, HDAdApoAI-treated arteries had significantly less vascular cell adhesion molecule-1 expression (28%; P=0.04) along with modest but statistically insignificant trends toward decreased intimal lesion volume, lipid and macrophage content, and intercellular adhesion molecule-1 expression (9%-21%; P=0.1-0.4). Post hoc subgroup analysis of rabbits with small-to-moderate-sized lesions (n=20) showed that HDAdApoAI caused large reductions in lesion volume, lipid content, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 expression (30%-50%; P≤0.04 for all). Macrophage content was reduced by 30% (P=0.06). There was a significant interaction (P=0.02) between lesion size and treatment efficacy.
Even when administered on a background of aggressive lowering of plasma cholesterol, local HDAdApoAI vascular gene therapy may promote rapid regression of small-to-moderate-sized atherosclerotic lesions.
直接将基因疗法应用于血管壁,有可能预防动脉粥样硬化病变的发展并促进动脉粥样硬化的消退。此前,我们报道过,在高脂喂养的兔子颈动脉内皮中表达载脂蛋白A-I(apoA-I)的辅助依赖型腺病毒(HDAd)载体可减少早期(4周)动脉粥样硬化病变的发展。在此,我们测试了将相同的HDAd应用于现有的颈动脉粥样硬化病变是否能促进病变消退。
将26只兔子高脂喂养7个月,然后进行双侧颈动脉基因转移治疗。一侧颈动脉注入表达apoA-I的HDAd(HDAdApoAI),另一侧注入不表达的对照HDAd(HDAdNull)。注入HDAdApoAI的一侧随机分配。然后将兔子改为常规饲料,使其血浆胆固醇降低超过70%。在HDAdApoAI转导的动脉中检测到apoA-I mRNA和蛋白。基因治疗7周后,与同一只兔子中接受HDAdNull治疗的动脉相比,接受HDAdApoAI治疗的动脉血管细胞黏附分子-1表达显著降低(28%;P=0.04),同时内膜病变体积、脂质和巨噬细胞含量以及细胞间黏附分子-1表达有适度但无统计学意义的下降趋势(9%-21%;P=0.1-0.4)。对有中小尺寸病变的兔子(n=20)进行事后亚组分析显示,HDAdApoAI使病变体积、脂质含量、细胞间黏附分子-1和血管细胞黏附分子-1表达大幅降低(30%-50%;所有P≤0.04)。巨噬细胞含量降低了30%(P=0.06)。病变大小与治疗效果之间存在显著交互作用(P=0.02)。
即使在积极降低血浆胆固醇的背景下给药,局部HDAdApoAI血管基因治疗仍可能促进中小尺寸动脉粥样硬化病变的快速消退。